- Trial phase
- Phase 3
- Time to market
- If Phase 3 succeeds, potential FDA submission would likely be in 2029-2030, with commercialization following 1-2 years later.
- Why 4/10
- The next hard catalyst for coramitug is the Phase 3 CLEOPATTRA trial primary completion, expected in 2029 (more than 12 months away). With no near-term binary catalyst, the impact score is set to the default of 4.
Coramitug has no near-term binary catalyst: the Phase 3 CLEOPATTRA trial's primary completion is expected in 2029. Watch for any interim analysis announcements from Novo Nordisk, which could move the stock if released early. The next major Prothena catalyst is the moponetug (PRX005) Phase 2 Alzheimer's data readout expected in 1H 2027, not coramitug.
Price Chart
Executive Summary
Coramitug (formerly PRX004) is a potential first-in-class amyloid-depleter antibody being developed by Novo Nordisk for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a progressive and fatal heart condition. Prothena (NASDAQ: PRTA) originally discovered the drug and licensed worldwide rights to Novo Nordisk in 2021, earning $150 million in milestone payments to date from a potential $1.2 billion total package. Phase 2 data showed statistically significant biomarker improvements but were described as mixed, and the Phase 3 CLEOPATTRA trial (~1,280 patients) is now enrolling with primary completion expected in 2029. The drug faces entrenched competition from Pfizer's tafamidis and Alnylam's recently approved vutrisiran. For Prothena investors, coramitug is a partnered, long-duration pipeline asset with no near-term catalyst.
How It Works
Coramitug is a monoclonal antibody (a lab-made protein that targets a specific substance in the body) designed to directly clear away amyloid deposits. In ATTR amyloidosis with cardiomyopathy, misfolded transthyretin proteins clump together as amyloid fibrils that build up in the heart muscle, stiffening it and leading to heart failure. Unlike existing drugs that only prevent new amyloid from forming (stabilizers like tafamidis) or reduce production of the TTR protein (gene silencers like vutrisiran), coramitug aims to actively remove existing amyloid deposits from the heart tissue.
Trial Status
The Phase 3 CLEOPATTRA trial is actively recruiting approximately 1,280 participants with ATTR-CM. The trial achieved a prespecified enrollment milestone in early 2026, triggering a $50 million payment from Novo Nordisk. Primary completion is expected in 2029. The FDA granted Fast Track designation in April 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 CLEOPATTRA trial primary completion (expected 2029) - no near-term binary catalyst
- Any potential interim analysis from Novo Nordisk (unconfirmed and not scheduled)
- Additional milestone payments from Novo Nordisk upon achieving development milestones
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PROTHENA CORP PUBLIC LTD CO 8-K PRTA ·Originating report